Modeling Leukemia Stem Cells with Patient-Derived Induced Pluripotent Stem Cells

Methods Mol Biol. 2021:2185:411-422. doi: 10.1007/978-1-0716-0810-4_26.

Abstract

Patient-derived induced pluripotent stem cells (iPSCs) have recently provided a new way to model acute myeloid leukemia (AML) and other myeloid malignancies. Here, we describe methods for the generation of patient-derived iPSCs from leukemia cells and for their subsequent directed in vitro differentiation into hematopoietic cells that recapitulate features of leukemia stem cells (LSCs) and leukemic blasts.

Keywords: AML; Human induced pluripotent stem cells; Reprogramming; hPSC-hematopoiesis; iPSC disease modeling.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Cellular Reprogramming*
  • Hematopoietic Stem Cells / metabolism*
  • Hematopoietic Stem Cells / pathology
  • Humans
  • Induced Pluripotent Stem Cells / metabolism*
  • Induced Pluripotent Stem Cells / pathology
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / metabolism*
  • Leukemia, Myeloid, Acute / pathology
  • Neoplastic Stem Cells / metabolism*
  • Neoplastic Stem Cells / pathology